Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia [Yahoo! Finance]
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Yahoo! Finance
First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to bexobrutideg (NX-5948) for the treatment of Waldenström macroglobulinemia (WM). Bexobrutideg is an orally bioavailable, brain penetrant degrader of BTK which is being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. The FDA's Orphan Drug Designation program provides orphan status to therapies intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. This designation
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Wells Fargo & Company from $21.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Mizuho from $24.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
NRIX
Earnings
- 10/9/25 - Miss
NRIX
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 144
- 12/9/25 - Form 8-K
- NRIX's page on the SEC website